Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Errico, F ^a,b   Nistico R ^c,d   Di Giorgio, A ^e   Squillace, M ^a   Vitucci, D ^a,f   Galbusera, A ^g   Piccinin, S ^h   Mango, D ^c   Fazio, L ⁱ   Middei, S ^c   Trizio, S ⁱ   Mercuri, N B ^c,j   Teule, M A ^c   Centonze, D ^c,j   Gozzi, A ^g   Blasi, G ⁱ   Bertolino, A ^i,k   Usiello, A ^a,l  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^g ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^h EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE OXIDASE; CYTOCHALASIN D; DEXTRO ASPARTIC ACID; MESSENGER RNA;

ANIMAL EXPERIMENT; ARTICLE; BRAIN BLOOD VOLUME; CATABOLISM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOARCHITECTURE; DENDRITIC CELL; ELECTROENCEPHALOGRAM; EXCITATORY POSTSYNAPTIC POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; GENETIC VARIABILITY; GRAY MATTER; GRAY MATTER VOLUME; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; IMAGE ANALYSIS; MALE; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM PARAMETERS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREFRONTAL CORTEX; WORKING MEMORY; ACTIN POLYMERIZATION; ADULT; ANIMAL CELL; BRAIN METABOLISM; BRAIN NERVE CELL; BRAIN SIZE; CELL STRUCTURE; DOSE RESPONSE; FEMALE; HUMAN; LONG TERM POTENTIATION; PYRAMIDAL NERVE CELL; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC TRANSMISSION;

EID: 84905239138     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.59     Document Type: Article

References (56)

1. Mothet JP, Snyder SH. Brain D-amino acids: a novel class of neuromodulators. Amino Acids 2012; 43: 1809-1810.
2. Snyder SH, Ferris CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000; 157: 1738-1751.
3. Fuchs SA, Berger R, de Koning TJ. D-serine: the right or wrong isoform? Brain Res 2011; 1401: 104-117.
4. Billard JM. D:-Amino acids in brain neurotransmission and synaptic plasticity. Amino Acids 2012; 43: 1851-1860.
5. Martineau M, Baux G, Mothet JP. D-serine signalling in the brain: friend and foe. Trends Neurosci 2006; 29: 481-491. (Pubitemid 44118443)
6. Wolosker H, Dumin E, Balan L, Foltyn VN. D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J 2008; 275: 3514-3526.
7. Balu DT, Coyle JT. Neuronal D-serine regulates dendritic architecture in the somatosensory cortex. Neurosci Lett 2012; 517: 77-81.
8. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci USA 2013; 110: E2400-E2409.
9. Bado P, Madeira C, Vargas-Lopes C, Moulin TC, Wasilewska-Sampaio AP, Maretti L et al. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl) 2011; 218: 461-470.
10. Zhang Z, Gong N, Wang W, Xu L, Xu TL. Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval. Cereb Cortex 2008; 18: 2391-2401.
11. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007; 90: 41-51. (Pubitemid 46177566)
12. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 767-769. (Pubitemid 40897791)
13. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-576. (Pubitemid 36682314)
14. D'Aniello A, Vetere A, Petrucelli L. Further study on the specificity of D-amino acid oxidase and D-aspartate oxidase and time course for complete oxidation of D-amino acids. Comp Biochem Physiol B 1993; 105: 731-734. (Pubitemid 23200130)
15. Errico F, Nistico R, Napolitano F, Mazzola C, Astone D, Pisapia T et al. Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging 2011; 32: 2229-2243.
16. Errico F, Nistico R, Palma G, Federici M, Affuso A, Brilli E et al. Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Mol Cell Neurosci 2008; 37: 236-246. (Pubitemid 351173847)
17. Errico F, Nistico R, Napolitano F, Oliva AB, Romano R, Barbieri F et al. Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiol Aging 2011; 32: 2061-2074.
18. Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G et al. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci 2008; 28: 10404-10414.
19. Kim PM, Duan X, Huang AS, Liu CY, Ming GL, Song H et al. Aspartate racemase, generating neuronal D-aspartate, regulates adult neurogenesis. Proc Natl Acad Sci USA 2010; 107: 3175-3179.
20. Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A et al. Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. J Psychiatr Res 2013; 47: 1432-1437.
21. Coyle JT. NMDA Receptor and Schizophrenia: A Brief History. Schizophr Bull 2012; 38: 920-926.
22. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37: 4-15.
23. Errico F, Pirro MT, Affuso A, Spinelli P, De Felice M, D'Aniello A et al. A physiological mechanism to regulate D-aspartic acid and NMDA levels in mammals revealed by D-aspartate oxidase deficient mice. Gene 2006; 374: 50-57.
24. Nistico R, Mango D, Mandolesi G, Piccinin S, Berretta N, Pignatelli M et al. Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One 2013; 8: e54666.
25. Rompala GR, Zsiros V, Zhang S, Kolata SM, Nakazawa K. Contribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes. PLoS One 2013; 8: e61278.
26. Ferrari L, Turrini G, Crestan V, Bertani S, Cristofori P, Bifone A et al. A robust experimental protocol for pharmacological fMRI in rats and mice. J Neurosci Methods 2012; 204: 9-18.
27. Gozzi A, Jain A, Giovannelli A, Bertollini C, Crestan V, Schwarz AJ et al. A neural switch for active and passive fear. Neuron 2010; 67: 656-666.
28. Sforazzini F, Schwarz AJ, Galbusera A, Bifone A, Gozzi A. Distributed BOLD and CBV-weighted resting-state networks in the mouse brain. Neuroimage 2014; 87: 403-415.
29. Dodero L, Damiano M, Galbusera A, Bifone A, Tsaftsaris SA, Scattoni ML et al. Neuroimaging evidence of major morpho-anatomical and functional abnormalities in the BTBR T+TF/J mouse model of autism. PLoS ONE 2013; 8: e76655.
30. Gozzi A, Tessari M, Dacome L, Agosta F, Lepore S, Lanzoni A et al. Neuroimaging evidence of altered fronto-cortical and striatal function after prolonged cocaine self-administration in the rat. Neuropsychopharmacology 2011; 36: 2431-2440.
31. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR et al. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 1998; 39: 615-624. (Pubitemid 28150996)
32. Schwarz AJ, Reese T, Gozzi A, Bifone A. Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 2003; 21: 1191-1200. (Pubitemid 38199724)
33. Gozzi A, Agosta F, Massi M, Ciccocioppo R, Bifone A. Reduced limbic metabolism and fronto-cortical volume in rats vulnerable to alcohol addiction. Neuroimage 2013; 69: 112-119.
34. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23 Suppl 1: S208-S219. (Pubitemid 39421720)
35. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011; 14: 69-76.
36. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011; 478: 519-523.
37. Colantuoni C, Henry G, Zeger S, Pevsner J. SNOMAD (Standardization and NOrmalization of MicroArray Data): web-accessible gene expression data analysis. Bioinformatics 2002; 18: 1540-1541. (Pubitemid 35414548)
38. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 2007; 3: 1724-1735. (Pubitemid 47510264)
39. Martino D, Di Giorgio A, D'Ambrosio E, Popolizio T, Macerollo A, Livrea P et al. Cortical gray matter changes in primary blepharospasm: a voxel-based morphometry study. Mov Disord 2011; 26: 1907-1912.
40. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798-1805. (Pubitemid 39314673)
41. Errico F, Napolitano F, Nistico R, Usiello A. New insights on the role of free D:-aspartate in the mammalian brain. Amino Acids 2012; 43: 1861-1871.
42. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013; 78: 81-93.
43. Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature 2004; 429: 761-766. (Pubitemid 38833127)
44. Okamoto K, Nagai T, Miyawaki A, Hayashi Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nat Neurosci 2004; 7: 1104-1112. (Pubitemid 41184451)
45. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycinsensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA 2002; 99: 467-472. (Pubitemid 34060384)
46. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of longlasting synaptic plasticity and memory. Neuron 2009; 61: 10-26.
47. Huang W, Zhu PJ, Zhang S, Zhou H, Stoica L, Galiano M et al. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci 2013; 16: 441-448.
48. Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 1999; 399: 66-70.
49. Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 1999; 283: 1923-1927.
50. Gong LQ, He LJ, Dong ZY, Lu XH, Poo MM, Zhang XH. Postinduction requirement of NMDA receptor activation for late-phase long-term potentiation of developing retinotectal synapses in vivo. J Neurosci 2011; 31: 3328-3335.
51. Huang YY, Nguyen PV, Abel T, Kandel ER. Long-lasting forms of synaptic potentiation in the mammalian hippocampus. Learn Mem 1996; 3: 74-85. (Pubitemid 26357733)
52. Lamprecht R, LeDoux J. Structural plasticity and memory. Nat Rev Neurosci 2004; 5: 45-54. (Pubitemid 38076183)
53. Wang SH, Morris RG. Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu Rev Psychol 2010; 61: 49-79, C1-4.
54. Javitt DC. Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull 2012; 38: 911-913.
55. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. Mol Med 2003; 9: 3-9. (Pubitemid 36667686)
56. Bertolino A, Blasi G. The genetics of schizophrenia. Neuroscience 2009; 164: 288-299.